The institute will still supply the AstraZeneca vaccine to Africa through the COVAX vaccine-sharing facility, John Nkengasong told reporters, but the African Union would seek additional supplies from Johnson & Johnson.
The statement comes the day after European and British medicine regulators said they had found possible links between AstraZeneca’s vaccine and reports of very rare cases of brain blood clots, but they reaffirmed its importance in protecting people.
Nkengasong said the possible link had nothing to do with the African Union’s decision. The bloc of 55 member states shifted its efforts to the Johnson & Johnson vaccine, he said, citing the deal signed last week to secure up to 400 million doses beginning in the third quarter of this year.
“…It was just a clear understanding of how not to duplicate efforts with the Serum Institute, so that we compliment each other rather than duplicate efforts,” he said.
(Reporting by Maggie Fick; Writing by Katharine Houreld; Editing by Alex Richardson and Nick Macfie)
Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]